Article
The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance.
Digestive diseases and sciences - 1 Apr 2011
Kim Moon-Chan, Jung Seok Won, Shin Jung Woo, Park Neung Hwa
Abstract excerpt
BACKGROUND AND AIMS: The aim of this study was to determine the optimal time and HBV DNA levels during the treatment period for prediction of virological breakthrough (VBT) 3 years after adefovir monotherapy in chronic hepatitis B (CHB) patients with lamivudine resistance. METHODS: We consecutively analyzed HBV DNA levels within 12 months in 210 lamivudine-resistant CHB patients treated with adefovir monotherapy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.